Fc-based scaffold engineering and advances
10.13200/j.cnki.cjb.004744
- VernacularTitle:基于Fc支架的工程化改造及进展
- Author:
Shujing LIANG
- Publication Type:Journal Article
- Keywords:
Monoclonal antibody drugs;
Neonatal Fc receptor(FcRn);
Monomeric Fc(mFc);
CH2;
CH3
- From:
Chinese Journal of Biologicals
2026;39(07):860-868+875
- CountryChina
- Language:Chinese
-
Abstract:
In recent years, therapeutic monoclonal antibody drugs have developed rapidly and are widely used in fields such as tumors, cancer, and immune diseases. However, most of the currently approved antibodies are full-size IgG1 antibodies,which have disadvantages such as large size and weak tissue penetration. To overcome this deficiency, the solution is to reduce the size without weakening the functionality. The key to the longer half-life of IgG lies in the Fc region. Therefore,engineering modification mainly involves constructing new Fc antibody scaffolds, which combine the characteristics of longer half-life, strong tissue penetration, and access binding ability to spatially restricted binding sites while having a smaller size,thereby improving the therapeutic effect. This paper reviews several Fc-based small molecule antibody fragments as scaffold models and their application prospects.
